Chromosome aberrations and telomere length modulation in bone marrow and spleen cells of melphalan-treated p53+/- mice

Environmental and Molecular Mutagenesis

Volumn 49, Issue 6, 2008, Pages 467-475

  Sgura, Antonella ^a   De Amicis, Andrea ^a   Stronati, Laura ^b   Cinelli, Serena ^c   Pacchierotti, Francesco ^b   Tanzarella, Caterina ^a  

^a ROMA TRE UNIVERSITY   (Italy)

^b ENEA C R CASACCIA   (Italy)

^c Research Toxicology Center   (Italy)

Author keywords

Chromosome aberration; Melphalan; p53+ mice; Telomere

Indexed keywords

MELPHALAN; PROTEIN P53;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE MARROW CELL; CHROMOSOME ABERRATION; CHROMOSOME SIZE; FLUORESCENCE IN SITU HYBRIDIZATION; GENOTYPE; MOUSE; NONHUMAN; SPLEEN CELL; TELOMERE; WILD TYPE;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BONE MARROW CELLS; CELLS, CULTURED; CHROMOSOME ABERRATIONS; CHROMOSOME PAINTING; FEMALE; GENOTYPE; IN SITU HYBRIDIZATION, FLUORESCENCE; MELPHALAN; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; SPLEEN; TELOMERE; TUMOR SUPPRESSOR PROTEIN P53;

MUS;

EID: 48249148137     PISSN: 08936692     EISSN: 10982280     Source Type: Journal    
DOI: 10.1002/em.20405     Document Type: Article

References (70)

1. Alexander P, Mikulski ZB. 1961. Differences in the response of leukaemia cells in tissue culture to nitrogen mustard and to dimethyl myleran. Biochem Pharmacol 5:275-282.
2. Attardi LD. 2005. The role of p53-mediated apoptosis as a crucial antitumor response to genomic instability: Lessons from mouse models. Mutat Res 569:145-157.
3. Bertrand P, Saintigny Y, Lopez BS. 2004. p53's double life: Transactivation-independent repression of homologous recombination. Trends Genet 20:235-243.
4. Bishop AJ, Hollander MC, Kosaras B, Sidman RL, Fornace AJ Jr, Schiestl RH. 2003. Atm-, p53, and Gadd45a-deficient mice show an increased frequency of homologous recombination at different stages during development. Cancer Res 63:5335-5343.
5. Blackburn EH. 2000. Telomere states and cell fates. Nature 408:53-56.
6. Blackburn EH. 2001. Switching and signaling at the telomere. Cell 106:661-673.
7. Blackburn AC, McLary SC, Naeem R, Luszcz J, Stockton DW, Donehower LA, Mohammed M, Mailhes JB, Soferr T, Naber SP, Otis CN, Jerry DJ. 2004. Loss of heterozygosity occurs via mitotic recombination in Trp53+/- mice and associates with mammary tumor susceptibility of the BALB/c strain. Cancer Res 64:5140-5147.
8. Blasco MA. 2005. Telomeres and human disease: Ageing, cancer and beyond. Nat Rev Genet 6:611-622.
9. Boley SE, Wong VA, French JE, Recio L. 2002. p53 heterozygosity alters the mRNA expression of p53 target genes in the bone marrow in response to inhaled benzene. Toxicol Sci 66:209-215.
10. Bouffler SD, Kemp CJ, Balmain A, Cox R. 1995. Spontaneous and ionizing radiation-induced chromosomal abnormalities in p53-deficient mice. Cancer Res 55:3883-3889.
11. Cerone MA, Londono-Vallejo JA, Bacchetti S. 2001. Telomere maintenance by telomerase and by recombination can coexist in human cells. Hum Mol Genet 10:1945-1952.
12. Chang PY, Torous D, Lutze-Mann L, Winegar R. 2000. Impact of p53 status on heavy-ion radiation-induced micronuclei in circulating erythrocytes. Mutat Res 466:87-96.
13. DePinho RA. 2000. The age of cancer. Nature 408:248-254.
14. Di Masi A, Antoccia A, Dimauro I, Argentino-Storino A, Mosiello A, Mango R, Novelli G, Tanzarella C. 2006. Gene expression and apoptosis induction in p53-heterozygous irradiated mice. Mutat Res 594:49-62.
15. Donner EM, Preston RJ 1996. The relationship between p53 status, DNA repair and chromatid aberration induction in G2 mouse embryo fibroblast cells treated with bleomycin. Carcinogenesis 171161-1165.
16. Dronkert ML, Kanaar R. 2001. Repair of DNA interstrand cross-links. Mutat Res 486:217-247.
17. Ducray C, Sabatier L. 1998. Role of chromosome instability in long term effect of manned-space missions. Adv Space Res 22:597-602.
18. Efthimiou M, Andrianopoulos C, Stephanou G, Demopoulos NA, Nikolaropoulos SS. 2007. Aneugenic potential of the nitrogen mustard analogues melphalan, chlorambucil and p-N,N-bis(2-chloroethyl)aminophenylacetic acid in cell cultures in vitro. Mutat Res 617:125-137.
19. Espejel S, Franco S, Rodríguez-Perales S, Bouffler SD, Cigudosa JC, Blasco MA. 2002. Mammalian Ku86 mediates chromosomal fusions and apoptosis caused by critically short telomeres. EMBO J 21:2207-2219.
20. Fan S, Smith ML, Rivet DJ, Duba D, Zhan Q, Kohn KW, Fornace AJ Jr, O'Connor PM. 1995. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res 55:1649-1654.
21. Fan S, Chang JK, Smith ML, Duba D, Fornace AJ Jr, O'Connor PM. 1997. Cells lacking CIP1/WAF1 genes exhibit preferential sensitivity to cisplatin and nitrogen mustard. Oncogene 14:2127-2136.
22. Fauth E, Scherthan H, Zankl H. 2000. Chromosome painting reveals specific patterns of chromosome occurrence in mitomycin C- and diethylstilboestrol- induced micronuclei. Mutagen 15:459-467.
23. French JE, Lacks GD, Trempus C, Dunnick JK, Foley J, Mahler J, Tice RR, Tennant RW. 2001. Loss of heterozygosity frequency at the Trp53 locus in p53-deficient (+/-) mouse tumors is carcinogen-and tissue-dependent. Carcinogenesis 22:99-106.
24. Gatz SA, Wiesmuller L. 2006. p53 in recombination and repair. Cell Death Differ 13:1003-1016.
25. Gilley D, Tanaka H, Herbert BS. 2005. Telomere dysfunction in aging and cancer. Int J Biochem Cell Biol 37:1000-1013.
26. Gottlieb E, Haffner R, King A, Asher G, Gruss P, Lonai P, Oren M. 1997. Transgenic mouse model for studying the transcriptional activity of the p53 protein: Age- and tissue-dependent changes in radiation-induced activation during embryogenesis. EMBO J 16:1381-1390.
27. Gould KA, Nixon C, Tilby MJ. 2004. p53 elevation in relation to levels and cytotoxicity of mono- and bifunctional melphalan-DNA adducts. Mol Pharmacol 66:1301-1309.
28. Greider CW. 1991. Telomeres. Curr Opin Cell Biol 3:444-451.
29. Griffith JD, Comeau L, Rosenfield S, Stansel RM, Bianchi A, Moss H, de Lange T. 1999. Mammalian telomeres end in a large duplex loop. Cell 97:503-514.
30. Gulezian D, Jacobson-Kram D, McCullough CB, Olson H, Recio L, Robinson D, Storer R, Tennant R, Ward JM, Neumann DA. 2000. Use of transgenic animals for carcinogenicity testing: Considerations and implications for risk assessment. Toxicol Pathol 28:482-499.
31. Healy LN, Pluta LJ, James RA, Janszen DB, Torous D, French JE, Recio L. 2001. Induction and time-dependent accumulation of micronuclei in peripheral blood of transgenic p53+/- mice, TgAC (v-Haras) and parental wild-type (C57BL/6 and FVB/N) mice exposed to benzene by inhalation. Mutagen 16:163-168.
32. Henson JD, Neumann AA, Yeager TR, Reddel RR. 2002. Alternative lengthening of telomeres in mammalian cells. Oncogene 21:598-610.
33. Holt D, Dreimanis M, Pfeiffer M, Firgaira F, Morley A, Turner D. 1999. Interindividual variation in mitotic recombination. Am J Hum Genet 65:1423-1427.
34. Ide F, Kitada M, Sakashita H, Kusama K. 2003. Reduction of p53 dosage renders mice hypersensitive to 7, 12-dimethylbenz(alpha) anthracene-induced salivary gland tumorigenesis. Anticancer Res 23:201-204.
35. Langer S, Kraus J, Jentsch I, Speicher MR. 2004. Multicolor chromosome painting in diagnostic and research applications. Chromosome Res 12:15-23.
36. Lazaro-Trueba I, Arias C, Silva A. 2006. Double bolt regulation of Rad51 by p53: A role for transcriptional repression. Cell Cycle 5:1062-1065.
37. Lee JM, Abrahamson JL, Kandel R, Donehower LA, Bernstein A. 1994. Susceptibility to radiation-carcinogenesis and accumulation of chromosomal breakage in p53 deficient mice. Oncogene 9:3731-3736.
38. Lengauer C, Kinzler KW, Vogelstein B. 1998. Genetic instabilities in human cancers. Nature 396:643-649.
39. Liang L, Shao C, Deng L, Mendonca MS, Stambrook PJ, Tischfield JA. 2002. Radiation-induced genetic instability in vivo depends on p53 status. Mutat Res 502:69-80.
40. Lin X, Howell SB. 2006. DNA mismatch repair and p53 function are major determinants of the rate of development of cisplatin resistance. Mol Cancer Ther 5:1239-1247.
41. Linke SP, Sengupta S, Khabie N, Jeffries BA, Buchhop S, Miska S, Henning W, Pedeux R, Wang XW, Hofseth LJ, Yang Q, Garfield SH, Sturzbecher HW, Harris CC. 2003. p53 interacts with hRAD51 and hRAD54, and directly modulates homologous recombination. Cancer Res 63:2596-2605.
42. Liu DY, Peng ZH, Qiu GQ, Zhou CZ. 2003. Expression of telomerase activity and oxidative stress in human hepatocellular carcinoma with cirrhosis. World J Gastroenterol 9:1859-1862.
43. Liu G, Parant JM, Lang G, Chau P, Chavez-Reyes A, El-Naggar AK, Multani A, Chang S, Lozano G. 2004. Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice. Nat Genet 36:63-68.
44. Lotem J, Sachs L. 1993. Hematopoietic cells from mice deficient in wild-type p53 are more resistant to induction of apoptosis by some agents. Blood 82:1092-1096.
45. Lu X, Lozano G, Donehower LA. 2003. Activities of wildtype and mutant p53 in suppression of homologous recombination as measured by a retroviral vector system. Mutat Res 522:69-83.
46. Mailhes JB. 1987. Incidence of aneuploidy in rodents. In: Vig BK, Sandberg AA, editors. Aneuploidy, Part A: Incidence and Etiology. New York: Alan R. Liss. pp 67-101.
47. Marty MS, Singh NP, Holsapple MP, Gollapudi BB. 1999. Influence of p53 zygosity on select sperm parameters of the mouse. Mutat Res 427:39-45.
48. McIlrath J, Bouffler SD, Samper E, Cuthbert A, Wojcik A, Szumiel I, Bryant PE, Riches AC, Thompson A, Blasco MA, Newbold RF, Slijepcevic P. 2001. Telomere length abnormalities in mammalian radiosensitive cells. Cancer Res 61:912-915.
49. Oikawa S, Kawanishi S. 1999. Site-specific DNA damage at GGG sequence by oxidative stress may accelerate telomere shortening. FEBS Lett 453:365-368.
50. Perrem K, Colgin LM, Neumann AA, Yeager TR, Reddel RR. 2001. Coexistence of alternative lengthening of telomeres and telomerase in hTERT-transfected GM847 cells. Mol Cell Biol 21:3862-3875.
51. Qiu H, Shimada K, Cheng Z. 1992. Chromosomal localization of the mouse prealbumin gene (Ttr) by in situ hybridisation. Cytogenet Cell Genet 61:186-188.
52. Ranaldi R, Palma S, Tanzarella C, Lascialfari A, Cinelli S, Pacchierotti F. 2007. Effect of p53 haploinsufficiency on melphalan-induced genotoxic effects in mouse bone marrow and peripheral blood. Mutat Res 615:57-65.
53. Razak ZR, Varkonyi RJ, Kulp-McEliece M, Caslini C, Testa JR, Murphy ME, Broccoli D. 2004. p53 differentially inhibits cell growth depending on the mechanism of telomere maintenance. Mol Cell Biol 24:5967-5977.
54. Rogan EM, Bryan TM, Hukku B, Maclean K, Chang AC, Moy EL, Englezou A, Warneford SG, Dalla-Pozza L, Reddel RR. 1995. Alterations in p53 and p16INK4 expression and telomere length during spontaneous immortalization of Li-Fraumeni syndrome fibroblasts. Mol Cell Biol 15:4745-4753.
55. Sgura A, Stronati L, Gullotta F, Pecis A, Cinelli S, Lascialfari A, Tanzarella C, Pacchierotti F. 2005. Use of chromosome painting for detecting stable chromosome aberrations induced by melphalan in mice. Environ Mol Mutagen 45:419-426.
56. Shao C, Stambrook PJ, Tischfield JA. 2001. Mitotic recombination is suppressed by chromosomal divergence in hybrids of distantly related mouse strains. Nat Genet 28:169-172.
57. Shelby MD, Gulati DK, Tice RR, Wojciechowski JP. 1989. Results of tests for micronuclei and chromosomal aberrations in mouse bone marrow cells with the human carcinogens 4-aminobiphenyl, treosulphan, and melphalan. Environ Mol Mutagen 13:339-342.
58. Sitte N, Saretzki G, von Zglinicki T. 1998. Accelerated telomere shortening in fibroblasts after extended periods of confluency. Free Radic Biol Med 24:885-893.
59. Slijepcevic P. 2006. The role of DNA damage response proteins at telomeres - An "integrative" model. DNA Repair (Amst) 5:1299-1306.
60. Spruill MD, Ramsey MJ, Swiger RR, Nath J, Tucker JD. 1996. The persistence of aberrations in mice induced by gamma radiation as measured by chromosome painting. Mutat Res 356:135-145.
61. Stronati L, Farris A, Pacchierotti F. 2004. Evaluation of chromosome painting to assess the induction and persistence of chromosome aberrations in bone marrow cells of mice treated with benzene. Mutat Res 545:1-9.
62. Tice RR, Furedi-Machacek M, Satterfield D, Udumudi A, Vasquez M, Dunnick JK. 1998. Measurement of micronucleated erythrocytes and DNA damage during chronic ingestion of phenolphthalein in transgenic female mice heterozygous for the p53 gene. Environ Mol Mutagen 31:113-124.
63. Tlsty TD. 1997. Genomic instability and its role in neoplasia. Curr Top Microbiol Immunol 221:37-46.
64. Torti VR, Cobb AJ, Wong VA, Butterworth BE. 2002. Induction of micronuclei in wild-type and p53(+/-) transgenic mice by inhaled bromodichloromethane. Mutat Res 520:171-178.
65. Venkatachalam S, Shi YP, Jones SN, Vogel H, Bradley A, Pinkel D, Donehower LA. 1998. Retention of wild-type p53 in tumors from p53 heterozygous mice: Reduction of p53 dosage can promote cancer formation. EMBO J 17:4657-4667.
66. Venkatachalam S, Tyner SD, Pickering CR, Boley S, Recio L, French JE, Donehower LA. 2001. Is p53 haploinsufficient for tumor suppression? Implications for the p53+/- mouse model in carcinogenicity testing. Toxicol Pathol 29 (Suppl):147-154.
67. Wang L, Cui Y, Lord BI, Roberts SA, Potten CS, Hendry JH, Scott D. 1996. Gamma-ray-induced cell killing and chromosome abnormalities in the bone marrow of p53-deficient mice. Radiat Res 146:259-266.
68. Wang ZM, Chen ZP, Xu ZY, Christodoulopoulos G, Bello V, Mohr G, Aloyz R, Panasci LC. 2001. In vitro evidence for homologous recombinational repair in resistence to melphalan. J Natl Cancer Inst 93:1473-1478.
69. Yatagai F, Morimoto S, Kato T, Honma M. 2004. Further characterization of loss of heterozygosity enhanced by p53 abrogation in human lymphoblastoid TK6 cells: Disappearance of endpoint hotspots. Mutat Res 560:133-145.
70. Yun S, Lie-A-Cheong C, Porter AC. 2004. Discriminatory suppression of homologous recombination by p53. Nucleic Acids Res 32:6479-6489.